{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:47:31Z","timestamp":1794030451936,"version":"4.8.0"},"reference-count":193,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,3,23]]},"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:p>Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (ICIs)\u2014 either as monotherapy or in combination with other ICIs or chemotherapy\u2014have demonstrated benefits in first-line therapy for advanced disease, the neoadjuvant and adjuvant settings, as well as in additional thoracic malignancies such as small cell lung cancer (SCLC) and mesothelioma. Challenging questions remain, however, on topics including therapy selection, appropriate biomarker-based identification of patients who may derive benefit, the use of immunotherapy in special populations such as people with autoimmune disorders, and toxicity management. Patient and caregiver education and support for quality of life (QOL) is also important to attain maximal benefit with immunotherapy. To provide guidance to the oncology community on these and other important concerns, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel of experts to develop a clinical practice guideline (CPG). This CPG represents an update to SITC\u2019s 2018 publication on immunotherapy for the treatment of NSCLC, and is expanded to include recommendations on SCLC and mesothelioma. The Expert Panel drew on the published literature as well as their clinical experience to develop recommendations for healthcare professionals on these important aspects of immunotherapeutic treatment for lung cancer and mesothelioma, including diagnostic testing, treatment planning, immune-related adverse events, and patient QOL considerations. The evidence- and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers using immunotherapy to treat patients with lung cancer or mesothelioma.<\/jats:p>","DOI":"10.1136\/jitc-2021-003956","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T08:25:31Z","timestamp":1653985531000},"page":"e003956","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02409342","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02477826","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02220894","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01905657","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03088540","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02409342","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02142738","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03088540","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02477826","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02220894","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01905657","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02366143","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02367781","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02008227","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03215706","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01642004","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01673867","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02578680","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02775435","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02125461","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02142738","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02409342","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02477826","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02220894","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02142738","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01295827","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01905657","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02578680","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02775435","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02366143","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02367781","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03215706","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02008227","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01642004","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01673867","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02125461","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02763579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03043872","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02763579","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03043872","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03066778","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03382561","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01928394","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02054806","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02628067","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02899299","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03158129","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02259621","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03816345","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03816332","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02008227","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03164616","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03409614","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03409614","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03164616","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03425643","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02504372","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03800134","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04025879","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03703297","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05060016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03703297","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05060016","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02784171","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Ramaswamy","family":"Govindan","sequence":"first","affiliation":[{"name":"Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charu","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J","family":"Antonia","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Medicine, Duke Cancer Institute Center for Cancer Immunotherapy, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Davies","sequence":"additional","affiliation":[{"name":"Yale School of Nursing, Yale Cancer Center, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M","family":"Dubinett","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ferris","sequence":"additional","affiliation":[{"name":"LUNGevity Foundation, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Forde","sequence":"additional","affiliation":[{"name":"Upper Aerodigestive Division, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7077-8801","authenticated-orcid":false,"given":"Edward B","family":"Garon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[{"name":"Thoracic and GI Malignancies Branch, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2670-9777","authenticated-orcid":false,"given":"Matthew D","family":"Hellmann","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred R","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Center for Thoracic Oncology, Tisch Cancer Institute and Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L","family":"Johnson","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute, Nashville, Tennessee, USA"},{"name":"Tennessee Oncology\/One Oncology, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shakun","family":"Malik","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment & Diagnosis, CTEP, National Cancer Institute, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Morgensztern","sequence":"additional","affiliation":[{"name":"Department of Medicine, Oncology Division, Medical Oncology, Washington University School of Medicine in Saint Louis, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel W","family":"Neal","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti D","family":"Patel","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Evanston, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5820-4397","authenticated-orcid":false,"given":"David L","family":"Rimm","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Sagorsky","sequence":"additional","affiliation":[{"name":"Upper Aerodigestive Division, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Radiology, Vagelos College of Physicians and Surgeons, Columbia University Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Sepesi","sequence":"additional","affiliation":[{"name":"Department of Thoracic and Cardiovascular Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy S","family":"Herbst","sequence":"additional","affiliation":[{"name":"Section of Medical Oncology, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"2026052722102117000_10.5.e003956.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"2026052722102117000_10.5.e003956.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"2026052722102117000_10.5.e003956.3","unstructured":"Food and Drug Administration . Bristol-Myers Squibb. OPDIVO (nivolumab) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125554"},{"key":"2026052722102117000_10.5.e003956.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.002"},{"key":"2026052722102117000_10.5.e003956.5","doi-asserted-by":"crossref","first-page":"9016","DOI":"10.1200\/JCO.2021.39.15_suppl.9016","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227","volume":"39","author":"Paz-Ares","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"2026052722102117000_10.5.e003956.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6"},{"key":"2026052722102117000_10.5.e003956.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7"},{"key":"2026052722102117000_10.5.e003956.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2026052722102117000_10.5.e003956.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136"},{"key":"2026052722102117000_10.5.e003956.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3062"},{"key":"2026052722102117000_10.5.e003956.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00228-2"},{"key":"2026052722102117000_10.5.e003956.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30641-0"},{"key":"2026052722102117000_10.5.e003956.13","doi-asserted-by":"crossref","first-page":"v710","DOI":"10.1093\/annonc\/mdz264","article-title":"IMpower133: updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC)","volume":"30","author":"Reck","year":"2019","journal-title":"Annals of Oncology"},{"key":"2026052722102117000_10.5.e003956.14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32714-8"},{"key":"2026052722102117000_10.5.e003956.15","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.002005"},{"key":"2026052722102117000_10.5.e003956.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012"},{"key":"2026052722102117000_10.5.e003956.17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.182.2.459"},{"key":"2026052722102117000_10.5.e003956.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030"},{"key":"2026052722102117000_10.5.e003956.19","unstructured":"Food and Drug Administration, Amgen Inc . IMDELLTRA (tarlatamab) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&amp;ApplNo=761344"},{"key":"2026052722102117000_10.5.e003956.20","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x"},{"key":"2026052722102117000_10.5.e003956.21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"2026052722102117000_10.5.e003956.22","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"2026052722102117000_10.5.e003956.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.03.030"},{"key":"2026052722102117000_10.5.e003956.24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9501"},{"key":"2026052722102117000_10.5.e003956.25","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000239"},{"key":"2026052722102117000_10.5.e003956.26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0593"},{"key":"2026052722102117000_10.5.e003956.27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398"},{"key":"2026052722102117000_10.5.e003956.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9501"},{"key":"2026052722102117000_10.5.e003956.29","unstructured":"Food and Drug Administration . Bristol-Myers Squibb. YERVOY (ipilimumab) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125377"},{"key":"2026052722102117000_10.5.e003956.30","unstructured":"Food and Drug Administration . Merck sharp Dohme. KEYTRUDA (pembrolizumab) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=125514"},{"key":"2026052722102117000_10.5.e003956.31","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-018-0469-6"},{"key":"2026052722102117000_10.5.e003956.32","first-page":"93","article-title":"Tremelimumab: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs (Abingdon Engl)"},{"key":"2026052722102117000_10.5.e003956.33","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0593"},{"key":"2026052722102117000_10.5.e003956.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346"},{"key":"2026052722102117000_10.5.e003956.35","doi-asserted-by":"crossref","unstructured":"Editors- Graham R , Mancher M , et al, Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice Guidelines . Clinical practice guidelines we can trust. National Academies Press (US), 2011.","DOI":"10.17226\/13058"},{"key":"2026052722102117000_10.5.e003956.36","doi-asserted-by":"crossref","first-page":"e192535-","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2026052722102117000_10.5.e003956.37","unstructured":"Food and Drug Administration, GlaxoSmithKline plc . JEMPERLI (dostarlimab) prescribing information. n.d. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761174"},{"key":"2026052722102117000_10.5.e003956.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.013"},{"key":"2026052722102117000_10.5.e003956.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026052722102117000_10.5.e003956.40","unstructured":"Food and Drug Administration, Genentech Inc . TECENTRIQ (atezolizumab) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761034"},{"key":"2026052722102117000_10.5.e003956.41","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1056\/NEJMoa1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-Selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"2026052722102117000_10.5.e003956.42","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced Non\u2013Small-Cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med Overseas Ed"},{"key":"2026052722102117000_10.5.e003956.43","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0624"},{"key":"2026052722102117000_10.5.e003956.44","unstructured":"Food and Drug Administration . Regeneron pharmaceuticals. LIBTAYO (cemiplimab) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761097"},{"key":"2026052722102117000_10.5.e003956.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.016"},{"key":"2026052722102117000_10.5.e003956.46","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2017.0013","article-title":"A prospective, multi-institutional, Pathologist-Based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","volume":"3","author":"Rimm","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026052722102117000_10.5.e003956.47","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"2026052722102117000_10.5.e003956.48","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0062"},{"key":"2026052722102117000_10.5.e003956.49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00073","article-title":"Landscape of microsatellite instability across 39 cancer types","volume":"2017","author":"Bonneville","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026052722102117000_10.5.e003956.50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.7293"},{"key":"2026052722102117000_10.5.e003956.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2014.11.005"},{"key":"2026052722102117000_10.5.e003956.52","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229179"},{"key":"2026052722102117000_10.5.e003956.53","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2016.34.15_suppl.3025","article-title":"Pd-L1 expression in advanced NSCLC: primary lesions versus metastatic sites and impact of sample age","volume":"34","author":"Midha","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"2026052722102117000_10.5.e003956.54","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167"},{"key":"2026052722102117000_10.5.e003956.55","doi-asserted-by":"crossref","first-page":"807","DOI":"10.6004\/jnccn.2018.0062","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 5.2018","volume":"16","author":"Ettinger","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2026052722102117000_10.5.e003956.56","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01099-7"},{"key":"2026052722102117000_10.5.e003956.57","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1200\/JCO.2017.76.7293","article-title":"Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of clinical oncology endorsement of the College of American pathologists\/international association for the study of lung cancer\/association for molecular pathology clinical practice guideline update","volume":"36","author":"Kalemkerian","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026052722102117000_10.5.e003956.58","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.critrevonc.2014.11.005","article-title":"Is there evidence for different effects among EGFR-TKIs? systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations","volume":"94","author":"Haspinger","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026052722102117000_10.5.e003956.59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7162"},{"key":"2026052722102117000_10.5.e003956.60","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11523-020-00745-7","article-title":"Efficacy and safety of crizotinib in the treatment of advanced non-small-cell lung cancer with ROS1 rearrangement or Met alteration: a systematic review and meta-analysis","volume":"15","author":"Vuong","year":"2020","journal-title":"Target Oncol"},{"key":"2026052722102117000_10.5.e003956.61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149"},{"key":"2026052722102117000_10.5.e003956.62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"2026052722102117000_10.5.e003956.63","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41416-020-01099-7","article-title":"A phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced\/metastatic non-small-cell lung cancer","volume":"124","author":"Creelan","year":"2021","journal-title":"Br J Cancer"},{"key":"2026052722102117000_10.5.e003956.64","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.739090","article-title":"Front-Line ICI-Based combination therapy Post-TKI resistance may improve survival in NSCLC patients with EGFR mutation","volume":"11","author":"Tian","year":"2021","journal-title":"Front Oncol"},{"key":"2026052722102117000_10.5.e003956.65","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT221"},{"key":"2026052722102117000_10.5.e003956.66","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0498"},{"key":"2026052722102117000_10.5.e003956.67","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02446"},{"key":"2026052722102117000_10.5.e003956.68","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0078"},{"key":"2026052722102117000_10.5.e003956.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.015"},{"key":"2026052722102117000_10.5.e003956.70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948"},{"key":"2026052722102117000_10.5.e003956.71","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.9001","article-title":"Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis","volume":"39","author":"Akinboro","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"2026052722102117000_10.5.e003956.72","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2020-CT221"},{"key":"2026052722102117000_10.5.e003956.73","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed Death-Ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncologist"},{"key":"2026052722102117000_10.5.e003956.74","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.19.02446","article-title":"Long-term outcomes and retreatment among patients with previously treated, programmed Death-Ligand 1\u2012Positive, advanced Non\u2012Small-Cell lung cancer in the KEYNOTE-010 study","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026052722102117000_10.5.e003956.75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01605"},{"key":"2026052722102117000_10.5.e003956.76","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.jtho.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-Specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026052722102117000_10.5.e003956.77","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic Nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"2026052722102117000_10.5.e003956.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009"},{"key":"2026052722102117000_10.5.e003956.79","unstructured":"Roche H-L . A study of Atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small cell lung cancer who have failed Platinum-Containing therapy (oak). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02008227"},{"key":"2026052722102117000_10.5.e003956.80","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-CT003"},{"key":"2026052722102117000_10.5.e003956.81","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/annonc\/mdy041","article-title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases","volume":"29","author":"Vokes","year":"2018","journal-title":"Ann Oncol"},{"key":"2026052722102117000_10.5.e003956.82","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1164"},{"key":"2026052722102117000_10.5.e003956.83","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jtho.2023.03.008","article-title":"Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial","volume":"18","author":"Makharadze","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026052722102117000_10.5.e003956.84","unstructured":"Food and Drug Administration . AstraZeneca. IMFINZI (durvalumab) prescribing information. Available: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761069"},{"key":"2026052722102117000_10.5.e003956.85","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cllc.2024.03.003","article-title":"A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study","volume":"25","author":"Garon","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"2026052722102117000_10.5.e003956.86","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with Durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med Overseas Ed"},{"key":"2026052722102117000_10.5.e003956.87","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the Pacific trial","volume":"31","author":"Paz-Ares","year":"2020","journal-title":"Ann Oncol"},{"key":"2026052722102117000_10.5.e003956.88","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"2026052722102117000_10.5.e003956.89","doi-asserted-by":"crossref","first-page":"CT003","DOI":"10.1158\/1538-7445.AM2021-CT003","article-title":"Abstract CT003: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial","volume":"81","author":"Forde","year":"2021","journal-title":"Cancer Res"},{"key":"2026052722102117000_10.5.e003956.90","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8503","article-title":"Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)","volume":"39","author":"Spicer","year":"2021","journal-title":"Journal of Clinical Oncology"},{"key":"2026052722102117000_10.5.e003956.91","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00793"},{"key":"2026052722102117000_10.5.e003956.92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.9000"},{"key":"2026052722102117000_10.5.e003956.93","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30098-5"},{"key":"2026052722102117000_10.5.e003956.94","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.071"},{"key":"2026052722102117000_10.5.e003956.95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02212"},{"key":"2026052722102117000_10.5.e003956.96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.109"},{"key":"2026052722102117000_10.5.e003956.97","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.cllc.2019.02.018","article-title":"Relationship between prior radiotherapy and Checkpoint-Inhibitor pneumonitis in patients with advanced non-small-cell lung cancer","volume":"20","author":"Voong","year":"2019","journal-title":"Clin Lung Cancer"},{"key":"2026052722102117000_10.5.e003956.98","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","article-title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026052722102117000_10.5.e003956.99","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"2026052722102117000_10.5.e003956.100","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"2026052722102117000_10.5.e003956.101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2015.01.043"},{"key":"2026052722102117000_10.5.e003956.102","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.08.017"},{"key":"2026052722102117000_10.5.e003956.103","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026052722102117000_10.5.e003956.104","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9000","article-title":"Randomized phase II clinical trial of cisplatin\/carboplatin and etoposide (Ce) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161","volume":"38","author":"Leal","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"2026052722102117000_10.5.e003956.105","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-179"},{"key":"2026052722102117000_10.5.e003956.106","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/now235"},{"key":"2026052722102117000_10.5.e003956.107","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2013.04.012"},{"key":"2026052722102117000_10.5.e003956.108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"2026052722102117000_10.5.e003956.109","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01238-6"},{"key":"2026052722102117000_10.5.e003956.110","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"2026052722102117000_10.5.e003956.111","unstructured":"Merck Provides Update on KEYTRUDA\u00ae (pembrolizumab) Indication in Metastatic Small Cell Lung Cancer in the US [press release] 2021."},{"key":"2026052722102117000_10.5.e003956.112","doi-asserted-by":"crossref","first-page":"214","DOI":"10.15585\/mmwr.mm6608a3","article-title":"Malignant Mesothelioma Mortality - United States, 1999-2015","volume":"66","author":"Mazurek","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026052722102117000_10.5.e003956.113","unstructured":"Jain SV , Wallen JM . Malignant mesothelioma. Treasure Island (FL): StatPearls, 2021."},{"key":"2026052722102117000_10.5.e003956.114","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026052722102117000_10.5.e003956.115","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081"},{"key":"2026052722102117000_10.5.e003956.116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6870"},{"key":"2026052722102117000_10.5.e003956.117","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.07.002"},{"key":"2026052722102117000_10.5.e003956.118","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0642-y"},{"key":"2026052722102117000_10.5.e003956.119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0712237105"},{"key":"2026052722102117000_10.5.e003956.120","doi-asserted-by":"publisher","DOI":"10.1038\/ncponc1183"},{"key":"2026052722102117000_10.5.e003956.121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"2026052722102117000_10.5.e003956.122","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2026052722102117000_10.5.e003956.123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.1644"},{"key":"2026052722102117000_10.5.e003956.124","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0895"},{"key":"2026052722102117000_10.5.e003956.125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.04.034"},{"key":"2026052722102117000_10.5.e003956.126","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/s41591-021-01541-0","article-title":"Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial","volume":"27","author":"Forde","year":"2021","journal-title":"Nat Med"},{"key":"2026052722102117000_10.5.e003956.127","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01224-2"},{"key":"2026052722102117000_10.5.e003956.128","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026052722102117000_10.5.e003956.129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026052722102117000_10.5.e003956.130","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.1200\/JCO.2015.61.6870","article-title":"Pseudoprogression and immune-related response in solid tumors","volume":"33","author":"Chiou","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026052722102117000_10.5.e003956.131","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2017.07.002","article-title":"Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review","volume":"59","author":"Queirolo","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2026052722102117000_10.5.e003956.132","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","author":"Di Giacomo","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"2026052722102117000_10.5.e003956.133","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0585-1"},{"key":"2026052722102117000_10.5.e003956.134","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncponc1183","article-title":"CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS","volume":"5","author":"Hodi","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"2026052722102117000_10.5.e003956.135","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00189"},{"key":"2026052722102117000_10.5.e003956.136","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026052722102117000_10.5.e003956.137","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"2026052722102117000_10.5.e003956.138","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435"},{"key":"2026052722102117000_10.5.e003956.139","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0047"},{"key":"2026052722102117000_10.5.e003956.140","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2026052722102117000_10.5.e003956.141","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01224-2"},{"key":"2026052722102117000_10.5.e003956.142","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0645-6"},{"key":"2026052722102117000_10.5.e003956.143","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005"},{"key":"2026052722102117000_10.5.e003956.144","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.2035"},{"key":"2026052722102117000_10.5.e003956.145","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.016"},{"key":"2026052722102117000_10.5.e003956.146","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N Engl J Med"},{"key":"2026052722102117000_10.5.e003956.147","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026052722102117000_10.5.e003956.148","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2019.05.002"},{"key":"2026052722102117000_10.5.e003956.149","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus Nonpalliative indications","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026052722102117000_10.5.e003956.150","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1016\/j.jtho.2019.08.424","article-title":"OA04.02 CheckMate 817: first-line nivolumab + ipilimumab in patients with ECoG PS 2 and other special populations with advanced NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"key":"2026052722102117000_10.5.e003956.151","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for immunotherapy of cancer (SITC) toxicity management Working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2026052722102117000_10.5.e003956.152","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000244"},{"key":"2026052722102117000_10.5.e003956.153","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.03.008"},{"key":"2026052722102117000_10.5.e003956.154","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026052722102117000_10.5.e003956.155","unstructured":"Butterfield LH , Kaufman HL , Johnson DH . SITC\u2019s Guide to Managing Immunotherapy Toxicity. 1 ed. New York: Springer Publishing Company."},{"key":"2026052722102117000_10.5.e003956.156","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.031872"},{"key":"2026052722102117000_10.5.e003956.157","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026052722102117000_10.5.e003956.158","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.585"},{"key":"2026052722102117000_10.5.e003956.159","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2017.02.008"},{"key":"2026052722102117000_10.5.e003956.160","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.cllc.2019.10.009","article-title":"Lower survival in patients who develop pneumonitis following immunotherapy for lung cancer","volume":"21","author":"Suresh","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"2026052722102117000_10.5.e003956.161","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S100685"},{"key":"2026052722102117000_10.5.e003956.162","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.resinv.2019.05.002","article-title":"Pre-Existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer","volume":"57","author":"Nakanishi","year":"2019","journal-title":"Respir Investig"},{"key":"2026052722102117000_10.5.e003956.163","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1188\/14.CJON.637-640","article-title":"Chemotherapy education for patients with cancer: a literature review","volume":"18","author":"Valenti","year":"2014","journal-title":"Clin J Oncol Nurs"},{"key":"2026052722102117000_10.5.e003956.164","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2014.001542"},{"key":"2026052722102117000_10.5.e003956.165","doi-asserted-by":"publisher","DOI":"10.1002\/pon.3055"},{"key":"2026052722102117000_10.5.e003956.166","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0279"},{"key":"2026052722102117000_10.5.e003956.167","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.03.008"},{"key":"2026052722102117000_10.5.e003956.168","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cllc.2016.12.010","article-title":"Evolution of symptom burden of advanced lung cancer over a decade","volume":"18","author":"Sung","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"2026052722102117000_10.5.e003956.169","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"2026052722102117000_10.5.e003956.170","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/thx.2004.031872","article-title":"Effect of lung cancer surgery on quality of life","volume":"60","author":"Win","year":"2005","journal-title":"Thorax"},{"key":"2026052722102117000_10.5.e003956.171","doi-asserted-by":"publisher","DOI":"10.1016\/0169-5002(95)00450-F"},{"key":"2026052722102117000_10.5.e003956.172","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/bjc.2013.585","article-title":"Quality of life during chemotherapy in lung cancer patients: results across different treatment lines","volume":"109","author":"Wintner","year":"2013","journal-title":"Br J Cancer"},{"key":"2026052722102117000_10.5.e003956.173","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.cllc.2017.02.008","article-title":"Emotional problems, quality of life, and symptom burden in patients with lung cancer","volume":"18","author":"Morrison","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"2026052722102117000_10.5.e003956.174","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1002\/pon.5025","article-title":"Assessing the psychosocial needs of newly diagnosed patients with nonsmall cell lung cancer: identifying factors associated with distress","volume":"28","author":"Leung","year":"2019","journal-title":"Psychooncology"},{"key":"2026052722102117000_10.5.e003956.175","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30690-3"},{"key":"2026052722102117000_10.5.e003956.176","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.05.011"},{"key":"2026052722102117000_10.5.e003956.177","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0382-2"},{"key":"2026052722102117000_10.5.e003956.178","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1200\/JOP.2014.001542","article-title":"Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study","volume":"11","author":"Zafar","year":"2015","journal-title":"J Oncol Pract"},{"key":"2026052722102117000_10.5.e003956.179","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2026052722102117000_10.5.e003956.180","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2012-0279"},{"key":"2026052722102117000_10.5.e003956.181","unstructured":"EuroQol . EQ-5D. Available: https:\/\/euroqol.org\/"},{"key":"2026052722102117000_10.5.e003956.182","unstructured":"European Organization for Research and Treatment of Cancer . Quality of life group website. Available: https:\/\/qol.eortc.org\/"},{"key":"2026052722102117000_10.5.e003956.183","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.570"},{"key":"2026052722102117000_10.5.e003956.184","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S0959-8049(05)80262-X","article-title":"Quality of life assessment in individuals with lung cancer: testing the lung cancer symptom scale (LCSS)","volume":"29A Suppl 1","author":"Hollen","year":"1993","journal-title":"Eur J Cancer"},{"key":"2026052722102117000_10.5.e003956.185","doi-asserted-by":"publisher","DOI":"10.1016\/0169-5002(95)00450-F"},{"key":"2026052722102117000_10.5.e003956.186","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1053\/j.seminoncol.2004.04.008","article-title":"The functional assessment of cancer therapy-lung and lung cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer","volume":"31","author":"Cella","year":"2004","journal-title":"Semin Oncol"},{"key":"2026052722102117000_10.5.e003956.187","first-page":"8","article-title":"Development of a functional assessment of chronic illness therapy item library and primary symptom list for the assessment of patient-reported adverse events associated with immune checkpoint modulators","volume":"6","author":"Webster","year":"2020","journal-title":"J Cancer Metastasis Treat"},{"key":"2026052722102117000_10.5.e003956.188","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/cncr.32692","article-title":"Development of the functional assessment of cancer therapy-immune checkpoint modulator (FACT-ICM): a toxicity subscale to measure quality of life in patients with cancer who are treated with ICMs","volume":"126","author":"Hansen","year":"2020","journal-title":"Cancer"},{"key":"2026052722102117000_10.5.e003956.189","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30690-3"},{"key":"2026052722102117000_10.5.e003956.190","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2018.05.011"},{"key":"2026052722102117000_10.5.e003956.191","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0382-2"},{"key":"2026052722102117000_10.5.e003956.192","doi-asserted-by":"crossref","first-page":"ii38","DOI":"10.1093\/annonc\/mdz063","article-title":"Final analysis of the phase 3 KEYNOTE-042 study: pembrolizumab (PEMBRO) versus platinum-based chemotherapy (chemo) as first-line therapy for patients (PTS) with PD-L1\u2013POSITIVE locally advanced\/metastatic NSCLC","volume":"30","author":"TSK","year":"2019","journal-title":"Ann Oncol"},{"key":"2026052722102117000_10.5.e003956.193","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:10:45Z","timestamp":1779945045000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":193,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5,31]]},"published-print":{"date-parts":[[2022,5]]}},"alternative-id":["10.1136\/jitc-2021-003956"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003956","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}